Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

DMCI Holdings Inc. PHP1(PREF)

Healthcare US DCHPF

NoneUSD
0.00(0%)

Last update at 2024-02-15T21:02:24.636593Z

Day Range

--
LowHigh

52 Week Range

30.0047.40
LowHigh

Fundamentals

  • Previous Close 46.90
  • Market Cap5568.48M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield1.16%
  • EBITDA62.20M
  • Revenue TTM761.50M
  • Revenue Per Share TTM6.71
  • Gross Profit TTM 429.60M
  • Diluted EPS TTM-0.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -36.10000M 77.60M 74.00M 40.90M 27.80M
Minority interest - - - - 0.00000M
Net income -27.90000M 58.20M 55.50M 33.90M 30.90M
Selling general administrative 359.20M 178.60M 151.30M 134.90M 125.70M
Selling and marketing expenses - - - - -
Gross profit 426.30M 384.80M 345.90M 291.60M 273.10M
Reconciled depreciation 89.70M 89.10M 15.50M 14.20M 9.80M
Ebit 17.10M 95.80M 87.00M 58.70M 50.60M
Ebitda - 178.90M 159.00M 122.00M 115.10M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 6.30M 170.10M 87.00M 58.70M 45.50M
Other operating expenses - - - - -
Interest expense 43.90M 12.20M 9.80M 11.50M 10.50M
Tax provision -8.20000M 19.40M 18.50M 7.00M -3.10000M
Interest income 0.80M 0.10M 0.00000M 0.10M 0.00000M
Net interest income -43.10000M -12.10000M -9.80000M -11.40000M -10.50000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -8.20000M 19.40M 18.50M 7.00M -3.10000M
Total revenue 761.50M 681.80M 608.00M 515.10M 481.80M
Total operating expenses 755.20M 511.70M 521.00M 456.40M 436.30M
Cost of revenue 335.20M 297.00M 262.10M 223.50M 208.70M
Total other income expense net - - - - -
Discontinued operations - - - - -
Net income from continuing ops -27.90000M 58.20M 55.50M 33.90M 30.90M
Net income applicable to common shares -27.90000M 58.20M 55.50M 33.90M 30.90M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 1569.40M 1293.30M 1214.10M 1237.60M 1048.50M
Intangible assets 587.90M 485.10M 479.70M 438.40M 434.90M
Earning assets - - - - -
Other current assets - - - - -
Total liab 814.20M 626.50M 581.20M 600.10M 539.40M
Total stockholder equity 755.20M 666.80M 632.90M 637.50M 509.10M
Deferred long term liab 5.10M 5.30M 5.60M 6.10M 5.50M
Other current liab 17.90M 21.70M 43.10M 37.60M 23.30M
Common stock 1.10M 1.10M 1.10M 1.10M 1.00M
Capital stock 1.10M 1.10M 1.10M 1.10M 1.00M
Retained earnings 86.60M 164.00M 147.70M 126.40M 124.20M
Other liab 149.60M 142.00M 109.90M 112.40M 107.40M
Good will 334.50M 245.40M 236.10M 253.80M 252.10M
Other assets 10.00M 7.60M 7.60M 8.80M 6.40M
Cash 74.40M 120.90M 118.40M 227.40M 80.30M
Cash and equivalents - - - - -
Total current liabilities 164.00M 158.70M 155.80M 137.30M 118.10M
Current deferred revenue - - - - -
Net debt 413.20M 192.80M 184.30M 112.60M 227.80M
Short term debt - - - - -
Short long term debt - - 0.00000M 1.40M 1.20M
Short long term debt total - - - - -
Other stockholder equity 71.70M 87.80M 72.50M 100.70M 106.00M
Property plant equipment 159.30M 100.30M 87.00M 76.40M 58.40M
Total current assets 467.90M 444.40M 392.20M 448.90M 291.50M
Long term investments - - - - -
Net tangible assets -162.10000M -58.40000M -77.30000M -48.60000M -166.00000M
Short term investments - - - - -
Net receivables 169.60M 142.10M 119.20M 97.30M 103.80M
Long term debt 487.60M 313.70M 302.70M 338.60M 306.90M
Inventory 217.30M 175.70M 149.50M 120.80M 103.50M
Accounts payable 43.40M 46.00M 35.20M 34.60M 31.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.30M
Deferred long term asset charges - - - - -
Non current assets total 1101.50M 848.90M 821.90M 788.70M 756.40M
Capital lease obligations 16.90M 15.40M 15.90M 15.00M -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -426.20000M -78.30000M -0.80000M -7.60000M -7.60000M
Change to liabilities -7.60000M 14.90M 20.30M 0.10M 6.30M
Total cashflows from investing activities -426.20000M -78.30000M -136.10000M -81.50000M -61.90000M
Net borrowings 186.30M -3.60000M -19.50000M 22.40M 7.30M
Total cash from financing activities 316.50M -46.10000M -55.10000M 118.90M -20.10000M
Change to operating activities - - - - -
Net income -27.90000M 58.20M 55.50M 33.90M 30.90M
Change in cash -46.50000M 2.50M -109.00000M 147.10M 0.60M
Begin period cash flow 120.90M 118.40M 227.40M 80.30M 79.70M
End period cash flow 74.40M 120.90M 118.40M 227.40M 80.30M
Total cash from operating activities 63.60M 122.90M 89.10M 106.40M 81.80M
Issuance of capital stock 181.90M 2.30M 2.30M 131.50M 1.20M
Depreciation 49.70M 43.70M 40.00M 25.80M 21.00M
Other cashflows from investing activities 0.80M 0.10M 0.10M 0.30M 0.30M
Dividends paid 51.70M 44.80M 37.90M 33.30M 28.40M
Change to inventory -31.10000M -19.30000M -36.60000M -15.70000M -14.10000M
Change to account receivables -21.50000M -23.40000M -19.70000M 6.90M -11.70000M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - -1.70000M -0.20000M
Change to netincome 62.00M 4.10M -20.90000M -2.60000M -16.20000M
Capital expenditures 22.80M 20.30M 18.90M 7.80M 12.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -60.20000M -27.80000M -36.00000M -8.70000M -19.50000M
Stock based compensation -0.80000M 3.30M 2.80M 1.50M 2.30M
Other non cash items 18.00M 2.40M 77.60M 75.60M 84.40M
Free cash flow 33.30M 45.30M -45.70000M 57.20M 59.30M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DCHPF
DMCI Holdings Inc. PHP1(PREF)		 - -% - - 20.28 7.29 5.59 7.99 62.39
LLY
Eli Lilly and Company		 14.63 1.37% 1078.78 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 0.35 0.16% 223.24 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 1.73 0.80% 217.13 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC		 -1.17 0.66% 176.28 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

View All

Profile

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

DMCI Holdings Inc. PHP1(PREF)

24 Cheshire Avenue, Northwich, United Kingdom, CW9 7UA

Key Executives

Name Title Year Born
Mr. Ian D. Page CEO, MD & Exec. Director 1961
Mr. Paul Nicholas Sandland MAAT, FCCA CFO & Exec. Director 1979
Dr. Anthony Gerard Griffin MD of Dechra Veterinary Products for Europe & Exec. Director 1963
Mr. Patrick Meeus Group Scientific Officer NA
Ms. Katy Clough Group HR Director NA
Mr. Mike Eldred Pres of North America 1970
Ms. Melanie Hall Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions